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Context. Episodic breathlessness is a relevant aspect in patients with advanced cancer.
Objectives. The aim of this study was to assess the different aspects of this clinical phenomenon.
Methods. A consecutive sample of patients with advanced cancer admitted to different settings for a period of six months
was surveyed. The presence of background breathlessness and episodic breathlessness, their intensity (numerical scale 0e10),
and drugs used for treatment were collected. Factors inducing episodic breathlessness and its influence on daily activities were
investigated.
Results. Of 921 patients, 29.3% (n ¼ 269) had breathlessness and 134 patients (49.8%) were receiving drugs for
background breathlessness. In the multivariate analysis, the risk of breathlessness increased with chronic obstructive
pulmonary disease, although it decreased in patients receiving disease-oriented therapy and patients with gastrointestinal
tumors. The prevalence of episodic breathlessness was 70.9% (n ¼ 188), and its mean intensity was 7.1 (SD 1.6). The
mean duration of untreated episodic breathlessness was 19.9 minutes (SD 35.3); 41% of these patients were receiving
drugs for episodic breathlessness. The majority of episodic breathlessness events (88.2%) were triggered by activity. In the
multivariate analysis, higher Karnofsky Performance Status levels were significantly related to episodic breathlessness,
although patients receiving disease-oriented therapy were less likely to have episodic breathlessness.
Conclusion. This study showed that episodic breathlessness frequently occurs in patients with breathlessness in the
advanced stage of disease, has a severe intensity, and is characterized by rapid onset and short duration, which require rapid
measures. J Pain Symptom Manage 2016;51:17e24.  2016 American Academy of Hospice and Palliative Medicine. Published by
Elsevier Inc. All rights reserved.
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Breathlessness is defined as a subjective experience
of breathing discomfort, commonly known as dys-
pnea, which consists of qualitatively distinct sensations
that vary in intensity.1 In the last days of life, breath-
lessness often becomes more severe and refractory to
traditional medical management. Breathlessness is a
disabling and distressing symptom reported by pa-
tients with advanced cancer, particularly in the last
three months of life and in patients with lung cancer,2
although it occurs in 46% of all cancer outpatients.3
Breathlessness is associated with significant suffering
both for patients and their caregivers. This symptom
is the most common chief complaint for admission
to hospital in patients with lung cancer.4
Breathlessness is a multifactorial problem gener-
ated through different modalities and pathways,
requiring complex and multiple interventions accord-
ing to the specific individual situation and the clinical
context. It may be caused by cancer itself, and
preexisting or concomitant comorbid conditions.5
This symptom may resemble the characteristics of
pain according to some temporal characteristics.
Although breathlessness may be a continuous phe-
nomenon present for most hours of the day, clearly
distinguishable episodes of intensified breathlessness
may overlap the background condition (episodic
breathlessness). As breathlessness is a complex entity
difficult to manage, it is of paramount importance
to gather data about this phenomenon to optimize
treatment and provide better and individualized
therapeutic options.
The aim of this observational prospective study was
to assess the prevalence of breathlessness and episodic
breathlessness, their characteristics, and possible fac-
tors implicated in their development in patients with
advanced cancer. The secondary aim was to assess
common treatments in a large number of patients.Patients and Methods
A consecutive sample of patients with advanced can-
cer admitted to seven different centers, which
included oncology, home care, palliative care unit,
or hospice settings, during a period of six months
(April 2014 to September 2014) was prospectively as-
sessed for this survey. All patients able to provide infor-
mation about breathlessness were eligible, and no
patient was excluded a priori.
Informed consent and institutional approval from
the University of Palermo were obtained. At the time
of admission, the epidemiological characteristics,
stage of disease, concomitant comorbidities, and
oncologic treatments were recorded. A specific
form was designed and filled in during the initialassessment visit. The researcher asked about the pres-
ence of breathlessness, its intensity on a numerical
scale from 0 to 10 (where 0 ¼ none and 10 ¼ worst
imaginable) over the past 24 hours, and drugs used
for its treatment, as part of the assessment. Patients
also were asked if they had episodic breathlessness
that was well distinguished from background breath-
lessness over the past 24 hours; possible factors
associated with episodic breathlessness; and if it
influenced daily activities or specific positions. Given
the multicenter nature of the study, a standardized
definition for episodic breathlessness (after agree-
ment of the Home Care Italy [HOCAI] study group)
was used: ‘‘a predictable or unpredictable increase
in breathlessness occurring intermittently, clearly
distinguishable in intensity from continuous breath-
lessness, if present.’’ When episodic breathlessness
occurred, intensity (on a numerical scale from 0 to
10 [where 0 ¼ none and 10 ¼ worst imaginable])
and duration were recorded. Finally, patients were
asked if they were receiving drugs for relieving such
episodes.
Statistical Analysis
According to previous studies, at least 900 patients
were necessary to gather data for more than 150
patients with episodic breathlessness. The statistical
analysis, to assess an association pattern between
breathlessness and clinical comorbidities, was carried
out by chi-square tests of statistical association, with a
confidence level of 5%. No correction for Type I error
was provided at this level because of its explorative
intent. Afterward, a logistic regression with outcome
variables, breathlessness, and episodic breathlessness
was performed adjusting for age and gender, pro-
viding the odds ratios of clinical and statistical impor-
tance. Model fitting was assessed by a likelihood ratio
test at a 5% Type I error level. Descriptive statistics of
the variables considered are provided. The analysis
was done with STATA version 13 (StataCorp LP, Col-
lege Station, TX).Results
A total of 921 patients were surveyed. The mean age
was 70.3 (SD 12.7) years, and 445 patients were male.
The primary tumors were, in a rank order, as follows:
lung 206 (22.6%), gastrointestinal 304 (33.4%), breast
94 (10.3%), hematological 83 (9.1%), urological 57
(6.2%), gynecological 51 (5.6%), brain 42 (4.6%),
prostate 35 (3.8%), head and neck 20 (2.2%), others
19 (2.1%), and unavailable data 10 (1%). Four hun-
dred seventeen patients (45.3%) were receiving
disease-oriented therapy, including chemotherapy,
hormonal therapy, or targeted therapy.
Table 2
Frequency of Breathlessness (BLN) According to the
Variables Taken Into Consideration
Variable BLN No BLN P-value
Age
#65 yrs 96 (36.2%) 208 (33.7%)
>65 yrs 169 (67.7%) 437 (63.7%) 0.14
Gender
Male 126 (46.84%) 318 (48.8%) 0.75
Female 143 (53.16%) 332 (51.2%)
Cancer
Lung 114 (43%) 92 (14.2%) 0.0000
Breast 20 (7.5%) 73 (11.4%)
Gynecological 11 (4.1%) 40 (6.3%)
Urological 13 (4.9%) 44 (6.9%)
Gastrointestinal 53 (20%) 250 (39.1%)
Hematological 27 (10.2%) 55 (8.6%)
Brain 8 (3%) 31 (4.8%)
Prostate 8 (3%) 27 (4.2%)
Head-neck 7 (2.6%) 13 (2%)
Others 4 (1.5%) 15 (2.3%)
Comorbidity
CVD 117 (43.5%) 257 (40.2%) 0.4
COPD 67 (25.3%) 59 (9.3%) 0.0000
Kidney disease 27 (10.1%) 57 (8.9%) 0.6
Liver disease 7 (2.6%) 18 (2.8%) 0.9
Karnofsky
#40 170 (63.2%) 384 (59.6%)
50e60 66 (24.5%) 169 (26.2%)
$70 33 (12.3%) 91 (14.1%) 0.0000
Treatment
Disease-oriented 109 (26.2%) 306 (73.5%)
Palliative care 156 (31.2%) 339 (67.9%) 0.11
CVD ¼ cardiovascular disease; COPD ¼ chronic obstructive pulmunary
disease.
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The prevalence of breathlessness was 29.3%
(n ¼ 269). In these patients, the mean intensity of
breathlessness was 4.2 (SD 1.9). One hundred thirty-
four patients (49.8%) were receiving drugs for back-
ground breathlessness. The categories of drugs are
listed in Table 1.
Associated comorbidities were, in a rank order, as fol-
lows: cardiovascular disease (41.1%), chronic obstruc-
tive pulmonary disease (COPD) (14%), renal failure
(9.3%), liver dysfunction (2.7%), and others (12.4%).
Breathlessness was significantly associated with age, can-
cer diagnosis, and disease-oriented therapy (Table 2).
In the multivariate analysis, the risk of breathlessness
increased with COPD, whereas it decreased in patients
receiving disease-oriented therapy and patients with
gastrointestinal tumors (Table 3).
Episodic Breathlessness
The prevalence of episodic breathlessness was
70.9% (n ¼ 188), and its mean intensity was 7.1 (SD
1.6). The mean duration of untreated episodic breath-
lessness was 19.9 minutes (SD 35.3). Of the 188 pa-
tients, 78 (41%) were receiving one or more drugs
for episodic breathlessness (Table 4).
The majority of episodic breathlessness events were
triggered by activity, including going upstairs (12.2%),
walking (20.2%), recumbency (6.4%), change of posi-
tion (9.6%), going upstairs and walking (26.3%), and
all (13.3%). In 11.8% of cases, no precipitant factors
were found.
In 133 patients (70.4%), episodic breathlessness
interfered with daily activities: going upstairs 12.3%,
walking 29.4%, recumbency 6.4%, change of position
9.7%, going upstairs and walking 26.3%, and all 15.6%.
Episodic breathlessness was significantly associated
with cancer diagnosis and Karnofsky Performance
Status (Table 5). In the multivariate analysis, higher
Karnofsky levels were significantly related to episodic
breathlessness, although patients receiving disease-
oriented therapy were less likely to have episodic
breathlessness (Table 6).Discussion
This study provides epidemiological data and char-
acterization of episodic breathlessness in a largeTable 1
Lists of Drugs Used for Breathlessness (in Some Cases,
Multiple Treatments)
Corticosteroids 85 (31.6%)
Opioids 46 (17.1%)
Benzodiazepines 8 (3%)
Bronchodilators 47 (17.5%)
Oxygen 41 (15.2%)sample of patients with advanced cancer, half of
them receiving disease-oriented therapy. About
one-third of patients (29.3%) had breathlessness
with significant intensity, and half were receiving a
background treatment, principally based on cortico-
steroids. Most of these patients had other health
conditions. Of this sample, a significant number of
patients (70.9%) had episodic breathlessness of severe
intensity clearly distinguishable from background
breathlessness, which lasted about 20 minutes and pri-
marily induced by activity.
Prevalence
The prevalence of breathlessness in advanced can-
cer patients has been reported to be variable, depend-
ing on the setting and stage of disease.3,6 In this
sample of patients with advanced cancer, we found a
breathlessness prevalence of about 30%, with a consis-
tent intensity, 4/10 on average. Different from pain, in
which some cutoff points to differentiate mild, moder-
ate, and severe intensity have been established, for
breathlessness, no specific studies have assessed how
much mild or moderate breathlessness is considered
to influence most daily activities.7
Existing data regarding episodic breathlessness in
the literature are sparse, despite a growing interest
in the last years. The definition used in this
Table 3
Multivariate Analysis for Breathlessness
Breathlessness Odds Ratio P > jzj 95% CI
Age 0.9772248 0.001 0.9637212 0.9909176
Gender 0.7009879 0.055 0.4876736 1.007609
Karnofsky 0.9950524 0.381 0.9840645 1.006163
Disease-oriented therapy 0.6398776 0.011 0.4540057 0.9018464
CVD 1.13644 0.456 0.8117733 1.590956
COPD 3.248147 0.000 2.098814 5.026866
Kidney disease 0.9534902 0.870 0.5398021 1.684216
Liver disease 0.7857181 0.646 0.2805056 2.200858
Lung 1.99209 0.173 0.7396618 5.365184
Gastrointestinal 0.3424446 0.036 0.1259366 0.931169
Urological 0.4482893 0.173 0.1412815 1.422432
Breast 0.3805674 0.089 0.1250216 1.158452
Hematological 0.9817316 0.973 0.3362079 2.86667
Gynecological 0.3707008 0.106 0.1111446 1.236399
Prostate 0.5881789 0.407 0.1676311 2.063784
Brain 0.5076033 0.267 0.1532334 1.681495
Others 0.5028533 0.373 0.1108688 2.280726
Head-neck Omitted because of collinearity
CVD ¼ cardiovascular disease; COPD ¼ chronic obstructive pulmunary disease. P ¼ 0.0000.
Table 4
Drugs Use to Relieve Episodic Breathlessness
Oxycodone 16 (20.5%)
Morphine 46 (59%)
Fentanyl mucosal products 4 (5.1%)
Benzodiazepines 5 (6.4%)
Bronchodilators 13 (16.7%)
Corticosteroids 17 (21.8%)
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Episodic breathlessness also has been considered as
incident dyspnea on a background of either irrevers-
ible dyspnea at rest or when speaking, in patients us-
ing a stable regular dose of an opioid,10 assuming
that the treatment should be reserved to opioid-
tolerant patients.
Controversies exist in the literature about the rela-
tionship and coexistence of breathlessness and
episodic breathlessness. In a qualitative study, 51 pa-
tients suffering from breathlessness from COPD,
lung cancer, and motor neuron disease were inter-
viewed. Patients described a clear relationship be-
tween breathlessness and episodic breathlessness.11
At the same time, 22% of interviewed patients had
episodic breathlessness only, without background
breathlessness. It is likely that the long duration
assigned for episodic breathlessness (less than
24 hours) was not clearly distinguishable from
breathlessness (longer than 24 hours), providing an
uncertain space, called out-of-the-blue,8 which was
able to confound these findings. On the other
hand, the mean duration of episodic breathlessness
(see the following) has been reported to be short,
within 10 minutes.12 This observation should limit
the definition of episodic breathlessness for episodes
with a shorter duration.
In a clinical study of advanced cancer patients with
dyspnea, 80% of patients experienced episodic breath-
lessness. However, despite the predefined definition
(aggravation of breathlessness. ), episodic breathless-
ness was recorded alone in 61% of patients, suggesting
that it often occurs without background breathless-
ness.9 But, a number of patients with constant breath-
lessness did not report episodic breathlessness. It is
likely that a misinterpretation of the questionnaire
may have biased the results, as confirmed by the higherintensity of constant breathlessness in comparison with
episodic breathlessness. Moreover, most patients with
obvious causes of breathlessness were excluded.9 In a
mixed population, episodes of breathlessness were
more severe and longer in patients with COPD than
in those with lung cancer; in cancer patients, 90% pre-
sented with more than three episodes a day.13Duration and Intensity
Although a real cutoff duration has never been
defined, it is likely that the temporal pattern should
circumscribe patients having episodic breathlessness
with a duration up to minutesehours; otherwise, it
could be defined as continuous breathlessness, persist-
ing for many hours of the day. For a similar temporal
phenomenon, breakthrough pain, most episodes last
less than one hour.14,15 Duration and intensity are
the most particular characteristics that may help in
providing a clear distinction with normal oscillations
in symptom intensity during the day. This also has a
relevant meaning in terms of therapeutic interven-
tions. In this study, the mean duration of episodic
breathlessness was about 20 minutes. In previous
patient-reported experiences described in the litera-
ture, the most frequent duration of episodic breath-
lessness was 5e15 minutes.9,13,16,17 Of concern, a risk
of recall bias cannot be excluded.
Table 5
Frequency of Episodic Breathlessness (EBLN) According
to the Variables Taken Into Consideration
Variable EBLN No EBLN P-value
Age
#65 yrs 65 (34.2%) 27 (38.6%)
>65 years 125 (65.8%) 43 (61.4%) 0.55
Gender
Male 90 (47.9%) 32 (45.7%)
Female 98 (52.1%) 38 (54.3%) 0.83
Cancer
Lung 75 (40.5%) 34 (48.6%) 0.03
Breast 20 (10.8%) 0
Gynecological 8 (4.3%) 4 (4.3%)
Urological 9 (4.9) 2 (2.9%)
Gastrointestinal 34 (18.4%) 17 (24.3%)
Hematological 22 (11.9%) 5 (7.1%)
Brain 3 (1.6%) 4 (5.7%)
Prostate 7 (3.8%) 1 (1.4%)
Head-neck 4 (2.2%) 3 (4.3%)
Others 3 (1.6%) 1 (1.4%)
Comorbidity
CVD 87 (46.3%) 25 (35.7%) 0.3
COPD 51 (27.6%) 14 (20.3%) 0.15
Kidney disease 18 (9.6%) 8 (11.4%) 0.86
Liver disease 4 (2.1%) 3 (4.3%) 0.6
Karnofsky
#30e40 113 (60.1%) 51 (72.8%)
50e60 45 (23.9%) 16 (22.9%)
$70 30 (16%) 3 (4.3%) 0.035
Treatment
Disease oriented 76 (72.4%) 29 (27.6%)
Palliative care 112 (71.8%) 44 (28.2%) 0.26
CVD ¼ cardiovascular disease; COPD ¼ chronic obstructive pulmunary
disease.
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episodic breathlessness, the intensity of episodic
breathlessness was higher (about 7/10) in comparison
with values of breathlessness (about 4/10); this helps
confirm the clear distinction in the definition of
episodic breathlessness, which is different from com-
mon oscillations throughout the day, and resembles
recent observations on breakthrough pain.18 ThisTable
Episodic Breathlessness
Episodic Breathlessness Odds Ratio
Age 0.9986193
Gender 1.086376
Karnofsky 1.043001
Disease-oriented therapy 0.4561336
CVD 1.814815
COPD 1.829534
Kidney disease 0.4824401
Liver disease 0.3415434
Lung 1.229628
Gastrointestinal 0.8152178
Urological 3.976354
Breast Omitted because of collinea
Hematological 2.609311
Gynecological 1.584504
Prostate 3.051325
Brain 0.1991798
Others 0.502853 3
Head-neck Omitted because of collinea
CVD ¼ cardiovascular disease; COPD ¼ chronic obstructive pulmunary disease.aspect has been recently assessed in an expert
consensus where episodic breathlessness was consid-
ered as a high-intensity episode distinguished from
usual fluctuations of breathlessness.8 On other occa-
sions, overlapping intensities of breathlessness and
episodic breathlessness were confounding factors.8,9
In the literature, the mean number of episodic breath-
lessness occurrences has been reported to be one to
five per day.12 We did not assess this number, as we ex-
pected that it was strongly dependent on the will or
the need to start an activity or not, as occurs with
breakthrough pain with an incident component
because of movement.Factors Inducing Episodic Breathlessness
Episodic breathlessness can be triggered (or not) by
identifiable factors, in particular by increasing physical
activity. Other triggers have been identified, including
emotional or environmental factors. In an interview-
based report of patients with different diseases, about
half of patients did not report any warning before an
episode.8 In this study, almost all episodes were pre-
dictable and triggered by activity. Raw measurements
at time of admission, patient selection, and a clear
definition may explain the differences found in this
study.
As for breathlessness,6 psychological factors often
have been reported as a possible cause of episodic
breathlessness.11 However, it is likely that the relation-
ship could be inverse, and episodic breathlessness con-
tributes to the development of anxiety and depression,
for its obvious influence on the psychological sphere,
although a vicious cycle with somatization cannot be
excluded.9
The interference of episodic breathlessness with
activities confirmed previous data.9 It is likely that6
Multivariate Analysis
P > jzj 95% CI
0.925 0.9704388 1.027618
0.797 0.5783075 2.04080
0.000 1.018839 1.067736
0.041 0.2145301 0.9698305
0.084 0.9237964 3.565237
0.128 0.8404821 3.982468
0.167 0.1717012 1.355543
0.243 0.0563634 2.069638
0.807 0.2347424 6.441036
0.818 0.1434317 4.633424
0.235 0.4083309 38.72201
rity
0.328 0.3817814 17.83351
0.682 0.1748755 14.3568
0.417 0.2057638 45.24888
0.175 0.0193269 2.052713
0.373 0.1108688 2.280726
rity
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extreme fatigue triggered by emotional, environ-
mental, or physical triggers. Fatigue is very common
symptom in advanced cancer patients and has been re-
ported to be correlated with high-intensity breathless-
ness.6,9 Meaningfully, fatigue may have a prominent
role, independent from a pulmonary problem.19
Therefore, indirectly, patients with fatigue may limit
or prevent episodic breathlessness by reducing their
level of activity. Interestingly, exercise has been used
as a model for inducing episodic breathlessness.20 It
could be surprising that episodic breathlessness is
more likely in patients with higher Karnofsky Perfor-
mance Status scores. Paradoxically, patients with a
higher Karnofsky score are more physically active
and, therefore, more likely to experience episodes of
breathlessness on exertion. These data are consistent
with the information reported for breakthrough pain
in oncology patients and those with far advanced can-
cer followed at home.21,22Cancer Diagnosis and Comorbidities
COPD had been found to be strongly associated
with background breathlessness, but not to episodic
breathlessness.17 It is likely that other factors, not
included in this analysis, may have flattened these
data. Fatigue could induce episodic breathlessness
when an activity is requested. Interestingly, patients
receiving disease-oriented therapy were less likely to
have episodic breathlessness. This aspect, as for pain,
is an interesting issue and deserves further study to
gather information about the relationship between
an oncology treatment and symptom intensity.Treatment of Breathlessness and Episodic
Breathlessness
Recent articles have focused their attention on
episodic breathlessness, suggesting some parallels
with the treatment of breakthrough pain. The tempo-
ral characteristics and duration of episodic breathless-
ness suggest a rapid intervention, independent from
the treatment of background breathlessness. Break-
through pain is an exacerbation of pain intensity on
a well-controlled background pain, generally treated
by opioids.14,15 However, different from background
pain intensity, it is quite difficult to define an ‘‘accept-
able’’ background breathlessness. Unlike chronic
pain, breathlessness poses therapeutic challenges, as
drugs commonly used have an indirect effect and
there are no specific first-choice treatments.
In this study, corticosteroids were found to be the
drugs most frequently administered, with opioids be-
ing used in a minority of patients. Of interest, the
administration of these drugs was focused on breath-
lessness, although the use for other purposes cannotbe excluded, as frequently it occurs in palliative care.
Despite these treatments, the mean level of breathless-
ness was 4/10, corresponding to a moderate intensity.
It would be interesting to establish the level of pa-
tients’ acceptability of these levels of breathlessness,
as occurs for background pain, and whether an opti-
mization of background treatment, for example, with
opioids, could be helpful; also, in increasing the toler-
ability of effort, thus reducing the occurrence of
episodic breathlessness. It has been suggested that
opioid-na€ıve patients could be slowly titrated because
inadequate dosing may generate no response.23
In this study, 40% of patients with episodic breathless-
ness were receiving a pharmacological treatment for it,
and about 80% of them were receiving oral opioids.
Oral opioids do not fit the temporal characteristics of
episodic breathlessness, as their effect starts about
30 minutes after administration.24 In a controlled trial
of patients receiving regular opioids, fixed doses of
inhaled hydromorphone produced an improvement
in episodic breathlessness 20 minutes after starting
nebulization, although this effect was not observed
with systemic administration or placebo.10 It is remark-
able that opioids were given for episodic breathlessness
to opioid-tolerant patients in fixed doses.
Fentanyl products have been ‘‘borrowed’’ from
breakthrough pain management for the treatment of
episodic breathlessness. This approach has been sug-
gested by the similar temporal characteristics of these
two phenomena. It is remarkable to note that trans-
mucosal fentanyl preparations are given to opioid-
tolerant patients for controlling background pain,24
although patients with breathlessness often do not
receive opioids chronically. This issue poses problems
of dosing fentanyl for episodic breathlessness. It is
reasonable that lower doses of fentanyl could be
titrated against the effect in opioid-na€ıve patients,
and higher doses would be necessary for opioids-
tolerant patients receiving opioids for chronic pain
or dyspnea. In another trial, doses of parenteral fenta-
nyl given prophylactically, proportional to opioids
given chronically (15e25%), were safe and effective.20
This study suggests that fentanyl products could be
given before an expected trigger, as it is for preventing
predictable breakthrough pain, for example, before
starting an activity.
Most case series provide promising effects.12 A ran-
domized controlled study demonstrated an improve-
ment in exercise tolerance after fixed doses of
inhaled fentanyl in comparison with placebo.25 How-
ever, this study was performed in noncancer patients
with pulmonary disease. Given the short onset and
duration of episodic breathlessness, it is likely that fen-
tanyl products with the fastest effect would be
preferred. Although some relief 15 minutes after
transmucosal administration of fentanyl26 has been
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study,27 possibly as a result of the slower onset of ac-
tion in comparison with new generations of fentanyl
delivery systems providing a clinical meaningful effect
within 5e15 minutes. Moreover, a patient with fatigue
experiencing episodic breathlessness is not fit enough
to rub the stick in the mouth. Of interest, other fenta-
nyl delivery systems are easier to use and do not need
specific patient participation.
This study had some limitations. First, the risk of
recall bias cannot be excluded in breathlessness evalu-
ation. The finding of no emotional triggers for breath-
lessness may be related to the way in which the
question was framed, and nonpharmacological ap-
proaches were not consequently assessed. The pre-
scription of some symptomatic drugs could be
associated with other clinical indications. Finally, the
role of fatigue was not assessed and could have a deter-
minant role in triggering the episodes.
In conclusion, data gathered from this study suggest
that episodic breathlessness frequently occurs in pa-
tients with breathlessness in the advanced stage of dis-
ease, has a severe intensity, and is characterized by
rapid onset and short duration that require rapid mea-
sures. These results should be interpreted with
caution, given the preliminary and observational na-
ture of the study. The generalizability of study results
should be confirmed in subclasses of patients with
different stages of disease, Karnofsky level, primary
diagnosis, comorbidities, and setting of care in a
larger number of patients. The influence of other
symptoms, such as fatigue, should be explored. Future
research should establish which level of background
breathlessness is acceptable for patients, as occurs
with chronic pain, and whether dose optimization
of background opioids given for breathlessness,
balancing antidyspneic effects and adverse effects,
may be useful in preventing or limiting the occurrence
of episodic breathlessness. Moreover, dosing of fenta-
nyl products for episodic breathlessness should be bet-
ter investigated according to the level of tolerance
provided by background opioids given for breathless-
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